Patent · US Active

Serum albumin binding molecules

US9540424B2 · kind B2 · utility

26Cited by

33References

19Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

Michael L. Gosselin · Boston, US
David Fabrizio · Hamilton, US
Joanna Swain · Concord, US
Tracy S. Mitchell · Andover, US
Ray Camphausen · Wayland, US
Sharon Cload · Cambridge, US
Eric Furfine · Concord, US
Paul E. Morin · Pennington, US
Ranjan Mukerjee · Nazareth, US
Simeon I. Taylor · Princeton, US

Key dates

Filing date	Nov 25, 2014
Grant date	Jan 10, 2017
Priority date	—
Expiry date	Jan 23, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/70
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.